GlassScriptPhysician profile
Michael T Wallace
NPI 1376922948
$6,793.94
in general payments reported to CMS, 2019-2025
22 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.37 · 2020: $148 · 2021: $313 · 2022: $96.58 · 2023: $263 · 2024: $5,399 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,027 · Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,027.00 |
| Food and Beverage | $1,165.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec Digital Innovations LLC | $5,027.00 | 2024 | Veracity Surgical |
| Abbvie INC. | $312.39 | 2023-2025 | Durysta, Xen Glaucoma Treatment System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $146.58 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $137.94 | 2023-2025 | Miebo, Vyzulta, Envista Mx60 Iol |
| Johnson & Johnson Surgical Vision, INC. | $137.62 | 2021 | |
| Glaukos Corporation | $135.38 | 2024 | Ce-Marked Kxla System |
| Alcon Vision LLC | $133.29 | 2019-2025 | Rocklatan |
| Biotissue Holdings INC. | $130.28 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $129.39 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $78.77 | 2020 | |
| Glaxosmithkline, LLC. | $58.11 | 2020-2021 | |
| Ocular Therapeutix, INC. | $53.13 | 2025 | Dextenza |
| New World Medical,INC. | $52.13 | 2023-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Dompe US, INC. | $51.33 | 2024-2025 | Oxervate |
| Antares Pharma, INC. | $46.99 | 2022-2023 | Tlando, Xyosted, Nocdurna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $30.78 | 2025 | Xdemvy |
| Rxsight INC | $26.15 | 2025 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Teva Pharmaceuticals USA, INC. | $25.24 | 2020 | |
| Abbott Laboratories | $24.84 | 2024 | Freestyle Libre 3 |
| Nova Eye, INC. | $20.39 | 2025 | |
| Astellas Pharma US INC | $19.33 | 2025 | Izervay |
| Genentech USA, INC. | $16.88 | 2024 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.